allogeneic anti-KK-LC-1 TCR NK-cell therapy (NCI/Zelluna Immunotherapy)

N/A

Report date: 2025/03/14 16:20:44

Base Information

Drug Nameallogeneic anti-KK-LC-1 TCR NK-cell therapy (NCI/Zelluna Immunotherapy)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Recombinant proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy

Mechanisms of ActionKita-kyushu lung cancer antigen 1 modulatorsHuman leukocyte antigen modulators

TargetsHuman leukocyte antigenKita-kyushu lung cancer antigen 1

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryNorway

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesNational Cancer Institute

China Registration ClassN/A

Develop Information

Active CompaniesZelluna Immunotherapy AS

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A